Every 30 seconds one person is dying from a hepatitis related illness. During the COVID-19 pandemic, there is a growing need to accelerate hepatitis elimination efforts. The TherVacB project team in Europe and Tanzania, working of clinical trial preparation on viral hepatitis B, remains fully dedicated to achieving the global elimination goal by 2030.
In times of COVID-19, European Testing Week aims to increase integrated testing efforts & promote awareness on the benefits of hepatitis and HIV testing!
This Spring European Testing Week 2021 and with COVID-19, we won’t be going back to “testing as usual”. Find out here about innovative testing strategies for viral hepatitis in times of COVID-19.
Now in its ninth year, the European campaign encourages partner organisations — in community, health care and policy institutions — throughout Europe to unite for one week in spring and in autumn to increase testing efforts and promote awareness on the benefits of earlier hepatitis and HIV testing.
Actually, European Testing Week supports testing activities throughout the year: To find out where you can have a test for HIV, hepatitis or other sexually transmitted infections use the European Test Finder. Hundreds of testing services for viral hepatitis, HIV and STIs are registered.
Find out more here.
Translations of the revised TherVacB website are now available in four languages!
To make info about the TherVacB vaccination study and the European HBV Registry more accessible to a Europen audience, we have partnered with researchers at study centres to produce this series of translations. The English version has now been joined by:
In addition to the TherVacB clinical trial, the TherVacB team has established a European registry for patients with chronic Hepatitis B. The European HBV Registry is currently active in Italy, Spain, UK and Germany and collects patient data on virological and immunological parameters during a hepatitis B virus infection. Every participant supports, with the data generated from him- or herself, to a better understanding of the HBV-mediated disease and to develop or refine therapies. Ultimately, this will help the community of patients in general!